China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization
Condition(s) studied
Investigational drug(s) / intervention(s)
No intervention; Observational study: No intervention; observational study
Study summary
Right heart catheterization(RHC) plays a crucial role in the diagnosis and treatment of pulmonary vascular diseases(PVD). In China, the lack of equipment and technical expertise has historically limited the implementation of RHC, thereby greatly restricting the diagnosis and treatment of RVD. In recent years, with improvements in these issues, more hospitals have acquired the capability to perform RHC. The purpose of this study is to conduct quality control of RHC across multiple pulmonary hypertension(PH) centers in China. The study population consists of patients who underwent RHC for the first time due to dyspnea or suspected PH. This study retrospectively and prospectively collects multicenter RHC data, with the main quality control contents including indications for the procedure, collection and analysis of hemodynamic data, diagnosis and treatment, and long-term management of patients.
Eligibility
Primary outcome measure(s)
- 3-month all cause death — 3 month
3-month all cause death
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| China-Japan Friendship Hospital | Beijing | China | Recruiting |
More China-Japan Friendship Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06954727 on ClinicalTrials.gov ↗ ← All trials in China